Symrise and Probi sign joint research and development agreement
Probi has signed a research and development agreement with the German company Symrise, a leading manufacturer of flavours, fragrances, cosmetics and health ingredients. In response to a growing consumer interest, the companies have decided to jointly develop innovative probiotic products with documented health benefits. The cooperation will initially focus on oral health.
Probi is a pioneer in research, development and manufacturing of probiotics. Probi’s probiotics are included in some of the most effective products for gut and immune health currently available on the global market. Expanding into new areas such as oral health will offer additional growth potential for the company.
Symrise has considerable expertise in research, development and manufacture of foods, beverages, cosmetics and pharmaceutical products and sees major potential in the health benefits of probiotics. The company also holds a globally leading position in the area of oral care.
The companies will collaborate to identify and examine various probiotic strains for use in oral health. Symrise has the capacity to screen and evaluate effects of active substances, which has made it possible to build a portfolio of active ingredients in cosmetics, nutrition and pharmaceuticals.
“The high level of expertise that Symrise possesses in sensory science, active ingredients and applications, combined with Probi’s expertise in probiotics, will provide us with the potential to jointly develop completely new and well-flavoured consumer products with distinct health benefits,” says Michael Oredsson, CEO of Probi AB.
“This partnership is a logical result of the growing demand for consumer products with documented health benefits. Our complementary expertise and strategic agendas in innovation will allow us to better support our customers in their development and marketing,” says Dr. Heinz-Jürgen Bertram, President of Symrise AG.
Symrise AG currently owns 14.97 % of the shares in Probi.
This is the type of information that Probi AB is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
FOR MORE INFORMATION, PLEASE CONTACT:
Michael Oredsson, CEO, Probi, tel. +46 46 286 89 23 or mobile +46 707 18 89 30, e-mail: michael.oredsson@probi.se
Gun-Britt Fransson, Vice President R&D, Probi, tel. +46 46 286 89 23 or mobile +46 705 95 73 27, e-mail: gun-britt.fransson@probi.se
ABOUT PROBI
Probi is a leading player in probiotic research and development of efficient and well-documented probiotics. Its research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi’s customer are leading companies in the Functional Foods and Consumer HealthCare business areas. Income for 2011 totalled MSEK 95.0. Probi’s share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. For more information, please visit www.probi.se.
ABOUT SYMRISE
Symrise is a global supplier of fragrances, flavours, cosmetic active ingredients and raw materials, as well as functional ingredients. Symrise develops new product ideas and market-ready concepts of practical value to the consumer by combining insight into consumer trends with cutting-edge technology and innovative development. Customers include producers of perfumes, cosmetics, food, pharmaceuticals and supplements. Sales for 2011 amounted to EUR 1.6 billion, placing Symrise among the four largest companies in the global aroma market. Read more at www.symrise.com.
Tags: